Current Trials
ACTIVE CLINICAL STUDIES AT THE CRCNJ
To find out if you’re eligible, contact us at 973 850 4622 or click on the link to the trial of interest, complete the online form, and we will contact you.
Actively Enrolling
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study)
SPONSOR: Cognito Therapeutics
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 345 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State Exam (MMSE).
clinicaltrials.gov.
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
SPONSOR: Acumen Pharmaceuticals
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
clinicaltrials.gov.
Active But Closed to Enrollment
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
SPONSOR: Eli Lilly
TRAILRUNNER-ALZ 1 is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of remternetug in participants with early symptomatic AD. Participants will receive remternetug or placebo administered via subcutaneous injection or intravenous infusion.
clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating The Safety And Efficacy Of Two Doses Of Simufilam In Subjects With Mild-To Moderate Alzheimer's Disease
SPONSOR: Cassava Sciences, Inc
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg tablets of simufilam, twice daily, for 76 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.
clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
SPONSOR: Eli Lilly
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
clinicaltrials.gov.
CLOSED TO ENROLLMENT
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
SPONSOR: Eli Lilly
The reason for this study is to see how safe and effective the study drug Donanemab is in participants with early Alzheimer's disease. clinicaltrials.gov.
For additional information, click here.
CLOSED TO ENROLLMENT
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
SPONSOR: Eli Lilly
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease.
clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
SPONSOR: Eli Lilly
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
CLOSED TO ENROLLMENT
Click here to make an appointment or call 973-850-4622 to learn more about how The CRCNJ can help.
